Titre :

Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).

Auteur(s) :

Gavriilaki, Eleni [Auteur]
General Hospital of Thessaloniki George Papanikolaou
Sakellari, Ioanna [Auteur]
General Hospital of Thessaloniki George Papanikolaou
Labopin, Myriam [Auteur]
CHU Saint-Antoine [AP-HP]
Bornhäuser, Martin [Auteur]
Technische Universität Dresden = Dresden University of Technology [TU Dresden]
Hamladji, Rose-Marie [Auteur]
Casper, Jochen [Auteur]
University of Oldenburg
Edinger, Matthias [Auteur]
University Hospital Regensburg
Zák, Pavel [Auteur]
Faculty of Medicine in Hradec Kralove [Republique Tchèque]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Ciceri, Fabio [Auteur]
Ospedale San Raffaele
Schroeder, Thomas [Auteur]
University Children's Hospital of Essen
Zuckerman, Tsila [Auteur]
Kobbe, Guido [Auteur]
University Hospital Düsseldorf
Yeshurun, Moshe [Auteur]
Narni, Franco [Auteur]
Azienda Ospedaleria Universitaria di Modena = University Hospital of Modena
Finke, Jürgen [Auteur]

Diez-Martin, Jose Luiz [Auteur]
Hospital General Universitario "Gregorio Marañón" [Madrid]
Berceanu, Ana [Auteur]
Hôpital JeanMinjoz
Hilgendorf, Inken [Auteur]
Verbeek, Mareike [Auteur]
Technische Universität Munchen - Technical University Munich - Université Technique de Munich [TUM]
Savani, Bipin [Auteur]
Vanderbilt University Medical Center [Nashville]
Spyridonidis, Alexandros [Auteur]
General University Hospital of Patras
Nagler, Arnon [Auteur]
Chaim Sheba Medical Center
Mohty, Mohamad [Auteur]
CHU Saint-Antoine [AP-HP]

Titre de la revue :

Bone Marrow Transplantation

Nom court de la revue :

Bone Marrow Transplant

Date de publication :

2023-07-09

ISSN :

1476-5365

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

We compared FT14 (fludarabine 150–160 mg/m2, treosulfan 42 g/m2) versus FB4 (fludarabine 150–160 mg/m2, busulfan 12.8 mg/kg) in acute myeloid leukemia (AML) transplanted at primary refractory/relapsed disease. We retrospectively ...
Lire la suite >We compared FT14 (fludarabine 150–160 mg/m2, treosulfan 42 g/m2) versus FB4 (fludarabine 150–160 mg/m2, busulfan 12.8 mg/kg) in acute myeloid leukemia (AML) transplanted at primary refractory/relapsed disease. We retrospectively studied: (a) adults diagnosed with AML, (b) recipients of first allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated/sibling donor (2010–2020), (c) HSCT with primary refractory/relapsed disease, (d) conditioning regimen with FT14 or FB4. We studied 346 patients, 113 transplanted with FT14, and 233 with FΒ4. FT14 patients were significantly older, more frequently had an unrelated donor and had received a lower dose of fludarabine. Cumulative incidence (CI) of acute graft-versus-host disease (GVHD) grade III-IV and extensive chronic GVHD was similar. With a median follow-up of 28.7 months, 2-year CI of relapse was 43.4% in FT14 versus 53.2% in FB4, while non-relapse mortality (NRM) was respectively 20.8% versus 22.6%. This led to 2-year leukemia-free survival (LFS) of 35.8% for FT14 versus 24.2% in FB4, and overall survival (OS) of 44.4% versus 34%. Adverse cytogenetics and conditioning regimen independently predicted CI of relapse. Furthermore, conditioning regimen was the only independent predictor of LFS, OS, and GVHD-free/relapse-free survival. Therefore, our real-world multicenter study suggests that FT14 is associated with better outcomes in primary refractory/relapsed AML.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-02-06T22:33:17Z
2024-03-20T15:47:03Z